eftilagimod alpha,pembrolizumab
merck,immutep
['pembro', 'eftilagimod', 'tacti-002']
#sitc22 | wade iams ( ) discusses the tacti-002 trial of eftilagimod alpha + pembro in 1st line #nsclc orr | 40% median dor | 21.6 mo encouraging orr + pfs in pd-l1 low pts #immunoonc #lcsm 